Peptide Blend Research Stack

Semax + Selank

The Semax + Selank stack is the most widely used cognitive peptide combination in nootropic research. Semax drives BDNF upregulation, cognitive activation, and neuroprotection. Selank provides anxiolytic modulation, emotional stability, and GABA system balancing. Together they produce a state of sharp cognitive performance without the anxiety or overstimulation that Semax alone can occasionally produce at higher doses.

Components 2 Peptides
Cycle Length 2–4 weeks, then 2-week break
Status Research Only
Stack Type Cognitive Stack

Synergy Rationale

Semax and Selank were both developed at the Institute of Molecular Genetics in Moscow, and their complementary profiles appear intentional. Semax produces cognitive activation via BDNF and dopaminergic upregulation — this drive and clarity can occasionally manifest as mild anxiety or overstimulation in sensitive individuals at higher doses.

Selank directly counteracts this through GABA-A modulation and enkephalin stabilisation — it is anxiolytic without sedation, meaning it buffers the edge of Semax's activation without blunting the cognitive benefits. The result is often described as "sharp and calm" — heightened mental clarity with emotional equilibrium.

Both compounds share the intranasal delivery route and reach the CNS via the same olfactory transport mechanism, making combination dosing practically straightforward. Their complementary receptor targets (dopaminergic vs GABAergic/opioidergic) mean there is no competition for the same binding sites — purely additive or synergistic effects.

Combined Mechanism of Action

Semax upregulates BDNF (brain-derived neurotrophic factor) mRNA in the cortex and hippocampus, supporting neuroplasticity, synaptic density, and neuronal survival. It also modulates serotonin and dopamine receptor sensitivity, producing motivational and cognitive sharpening effects.

Selank allosterically modulates GABA-A receptors and inhibits the enzymes that degrade enkephalins (endogenous opioid peptides). The resulting elevation in enkephalin tone produces anxiolytic, mood-stabilising effects without receptor downregulation or dependence — unlike benzodiazepines.

The combination produces a CNS environment where BDNF-driven neuroplasticity and dopaminergic activation (Semax) is stabilised by GABAergic and opioidergic balance (Selank) — creating the cognitive clarity + emotional groundedness that makes this stack particularly valued for high-performance intellectual work.

Research Evidence

Both compounds are approved in Russia for clinical use. Combination use is common in Russian nootropic research practice. Western RCT data on the combination is absent, but the complementary mechanism profiles are well-characterised individually.

Neuropharmacology (2003)

Semax Modulates Serotonin and Dopamine Receptor Activity

Semax produced dose-dependent changes in monoamine receptor sensitivity in rat brain, including serotonin 5-HT2A and dopaminergic pathways, consistent with cognitive-enhancing and neuroprotective profiles.

Bull Exp Biol Med (2008)

Selank Anxiolytic Effects Without Tolerance or Dependence

Selank produced comparable anxiolytic effects to diazepam in multiple animal models without motor impairment, sedation, or tolerance after 21 days of continuous administration.

Research Protocol Reference

Component Dosing Protocol

⚠️ For educational reference only. Not medical advice. Consult a qualified healthcare professional before any peptide use.
Semax
Dose200–400 mcg
Frequency1–2× daily
RouteIntranasal spray
TimingMorning (and optionally midday)
Selank
Dose250–500 mcg
Frequency1–2× daily
RouteIntranasal spray
TimingSame time as Semax, or as needed for anxiety management
Recommended Cycle 2–4 weeks, then 2-week break

Both are available in N-Acetyl forms (NA-Semax, NA-Selank) with improved stability and potency. Many researchers use them simultaneously — one spray of each in each nostril. Avoid evening dosing of Semax to prevent sleep disruption; Selank can be used in the evening if needed for anxiety management.

Safety Considerations

Reported Side Effects

  • Nasal irritation (both)
  • Mild initial headache (Semax)
  • Occasional overstimulation at high Semax doses (balanced by Selank)

Contraindications

  • Active psychotic disorders
  • Epilepsy/seizure history
  • Pregnancy
  • MAO inhibitor use (caution with monoamine modulation)

Frequently Asked Questions

Should Semax and Selank be taken at the same time?+

Yes — most researchers administer both simultaneously as part of the same morning routine. They can be administered from separate nasal sprays one after the other, or mixed into a single nasal spray bottle if using the same solvent. There is no known interaction between the two, and combining them at the same time takes advantage of their complementary onset windows.

Is this stack suitable for everyday use?+

Short cycles of 2–4 weeks are the standard approach, followed by 1–2 week breaks. Both compounds are generally well-tolerated without dependence, but cycling prevents adaptation and preserves sensitivity to their effects. Some researchers use one day on/one day off instead of continuous dosing.

What is the best ratio of Semax to Selank?+

1:1 by dose is the most common ratio (e.g., 300 mcg each, or 200 mcg each of NA-Semax and NA-Selank). Some researchers titrate Selank higher (e.g., 1:2 Semax:Selank) if Semax-associated overstimulation is a concern, or higher Semax if maximum cognitive drive is the goal. There is no established optimal ratio from controlled research.

Can Semax + Selank be used for exam preparation or creative work?+

This is one of the most commonly described research applications. The combination's profile — Semax-driven BDNF upregulation and cognitive activation with Selank-mediated anxiety reduction — describes a state well-suited to sustained mental performance: sharp focus, high working memory, and emotional stability without the anxiety that can accompany stimulants or high-dose nootropics.

Are there withdrawal effects from the Semax + Selank stack?+

No dependence or withdrawal phenomena have been documented for either compound individually in research studies up to 30 days. Selank's anxiolytic effect comes without GABA receptor downregulation. Some users report a mild "flat" feeling in the first few days after stopping Semax, attributed to BDNF level normalisation, but this is transient and not a clinical withdrawal syndrome.

Key Research References

  1. Dolotov OV et al. (2006). Semax, an analogue of ACTH(4-7), regulates BDNF and TrkB expression. J Neurochem.
  2. Zozulya AA et al. (2001). The inhibitory effect of Selank on enkephalin-degrading enzymes. Bull Exp Biol Med.

Explore more peptide combination stacks

Browse All Blends →